Author: Suárez-GarcÃa, Inés; Perales-Fraile, Isabel; González-GarcÃa, Andrés; Muñoz-Blanco, Arturo; Manzano, Luis; Fabregate, MartÃn; DÃez-Manglano, Jesús; Aizpuru, Eva Fonseca; Fernández, Francisco Arnalich; GarcÃa, Alejandra GarcÃa; Gómez-Huelgas, Ricardo; Ramos-Rincón, José-Manuel
Title: In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain Cord-id: klojaneu Document date: 2021_8_3
ID: klojaneu
Snippet: BACKGROUND: Whether immunosuppressed (IS) patients have a worse prognosis of COVID-19 compared to non-IS patients is not known. The aim of this study was to evaluate the clinical characteristics and outcome of IS patients hospitalized with COVID-19 compared to non-IS patients. METHODS: We designed a retrospective cohort study. We included all patients hospitalized with laboratory-confirmed COVID-19 from the SEMI-COVID-19 Registry, a large multicentre national cohort in Spain, from March 27(th) u
Document: BACKGROUND: Whether immunosuppressed (IS) patients have a worse prognosis of COVID-19 compared to non-IS patients is not known. The aim of this study was to evaluate the clinical characteristics and outcome of IS patients hospitalized with COVID-19 compared to non-IS patients. METHODS: We designed a retrospective cohort study. We included all patients hospitalized with laboratory-confirmed COVID-19 from the SEMI-COVID-19 Registry, a large multicentre national cohort in Spain, from March 27(th) until June 19(th), 2020. We used multivariable logistic regression to assess the adjusted odds ratios (aOR) of in-hospital death among IS compared to non-IS patients. RESULTS: Among 13 206 included patients, 2 111 (16.0%) were IS. A total of 166 (1.3%) patients had solid organ (SO) transplant, 1081 (8.2%) had SO neoplasia, 332 (2.5%) had hematologic neoplasia, and 570 (4.3%), 183 (1.4%) and 394 (3.0%) were receiving systemic steroids, biological treatments, and immunosuppressors, respectively. Compared to non-IS patients, the aOR (95% CI) for in-hospital death was 1.60 (1.43–1.79) for all IS patients, 1.39 (1.18–1.63) for patients with SO cancer, 2.31 (1.76–3.03) for patients with haematological cancer and 3.12 (2.23–4.36) for patients with SO transplant. The aOR (95% CI) for death for patients who were receiving systemic steroids, biological treatments and immunosuppressors compared to non-IS patients were 2.16 (1.80–2.61), 1.97 (1.33–2.91) and 2.06 (1.64–2.60), respectively. IS patients had a higher odds than non-IS patients of in-hospital acute respiratory distress syndrome, heart failure, myocarditis, thromboembolic disease and multiorgan failure. CONCLUSIONS: IS patients hospitalized with COVID-19 have a higher odds of in-hospital complications and death compared to non-IS patients.
Search related documents:
Co phrase search for related documents- absolute difference and acute heart failure: 1
- absolute difference and acute myocardial infarction: 1
- absolute difference and acute respiratory distress syndrome: 1, 2, 3
- absolute difference and admission invasive ventilation: 1
- active cancer and acute limb ischemia: 1
- active cancer and acute renal failure: 1
- active cancer and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
- active cancer and admission invasive ventilation: 1, 2
- active cancer treatment and acute respiratory distress syndrome: 1, 2
- active chemotherapy and acute limb ischemia: 1
- active chemotherapy and acute respiratory distress syndrome: 1, 2
- acute heart failure and admission invasive ventilation: 1, 2
- acute myocardial infarction and admission invasive ventilation: 1
- acute renal failure and admission invasive ventilation: 1
- acute respiratory distress syndrome and admission chest radiography: 1
- acute respiratory distress syndrome and admission invasive ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory distress syndrome and admission laboratory test: 1
Co phrase search for related documents, hyperlinks ordered by date